<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111770</url>
  </required_header>
  <id_info>
    <org_study_id>ECRI-013</org_study_id>
    <nct_id>NCT04111770</nct_id>
  </id_info>
  <brief_title>The OPTIMAL Randomized Controlled Trial</brief_title>
  <acronym>OPTIMAL</acronym>
  <official_title>OPtimizaTIon of Left MAin PCI With IntravascuLar Ultrasound. The OPTIMAL Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECRI bv</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philips Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ECRI bv</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OPTIMAL study is a randomized, controlled, multicentre, international study. A total of
      800 patients will be randomized in a 1:1 fashion to Intravascular Ultrasound (IVUS)-guided
      PCI versus qualitative angio(QCA)-guided Percutaneous Coronary Intervention (PCI). Patients
      will be consented prior to the PCI procedure and then followed up to 2 years after the index
      procedure.

      Patients will be followed-up at 1 month (telephone contact), 12 months (outpatient clinic
      visit or telephone call) and 24 months (outpatient clinic visit or telephone call) after the
      index procedure.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-oriented Composite Endpoint (POCE)</measure>
    <time_frame>2 years follow up</time_frame>
    <description>Patient-oriented Composite Endpoint (PoCE): composite of all-cause death, any stroke, any myocardial infarction (MI)*, any clinically indicated revascularization at 2 years follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device-oriented Composite Endpoint (DoCE)</measure>
    <time_frame>1 and 2 years follow up</time_frame>
    <description>Device-oriented Composite Endpoint (DoCE) defined as the composite of: Cardiovascular death, target vessel MI, clinically indicated repeat revascularization of the target lesion at 1 and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vessel-oriented Composite Endpoint (VoCE)</measure>
    <time_frame>1 and 2 years follow up</time_frame>
    <description>Vessel-oriented Composite Endpoint (VoCE) defined as the composite of: left main related cardiac death, target vessel MI, clinically indicated -repeat revascularization of the left main vessels at 1 and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented Composite Endpoint (POCE)</measure>
    <time_frame>1 year follow up</time_frame>
    <description>Patient-oriented Composite Endpoint (PoCE): composite of all-cause death, any stroke, any myocardial infarction (MI)*, any clinically indicated revascularization at 2 years follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All individual components of PoCE at all time points.</measure>
    <time_frame>1 and 2 years follow up</time_frame>
    <description>All individual components of PoCE at all time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All individual components of DoCE at all time points.</measure>
    <time_frame>1 and 2 years follow up</time_frame>
    <description>All individual components of DoCE at all time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite and probable stent thrombosis</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Definite and probable stent thrombosis according to ARC definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>2 years</time_frame>
    <description>Investigator reported hospitalization for heart failure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Left Main Coronary Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>IVUS guided PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QCA guided PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QCA will be used to determine lesion characteristics</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IVUS guided Percutaneous Coronary Intervention</intervention_name>
    <description>Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.</description>
    <arm_group_label>IVUS guided PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>QCA guided Percutaneous Coronary Intervention</intervention_name>
    <description>QCA will be used to determine lesion characteristics</description>
    <arm_group_label>QCA guided PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must be â‰¥ 18 years of age;

          2. De novo lesion of the LM (ostial, shaft or distal) where PCI is considered appropriate
             and feasible by the Heart Team*.

          3. Stable or unstable angina, non-ST segment myocardial infarction, documented silent
             ischemia or a positive functional study (e.g. by pressure or angiography derived
             indices).

          4. Any left-main Medina classification 100, 110, 101, 011, 010, 111, 001 (left-main
             equivalent) can be included.

          5. A patient with a previous coronary artery bypass graft (CABG) with no patent bypass on
             the LCA may be included.

          6. Able to understand and provide informed consent and comply with all study procedures,
             including follow-up for at least 2 years.

        Exclusion Criteria:

          1. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed
             within 7 days prior to the index procedure in women of child-bearing potential).

          2. Ongoing MI or recent MI with cardiac biomarker levels still elevated.

          3. Previous history of CABG with patent Left Internal Mammary Artery (LIMA) to LAD and/or
             patent graft to the left circumflex coronary.

          4. Prior PCI of the left-main or the ostium of the LAD or the ostium of the LCX at any
             time prior to enrolment.

          5. Prior PCI in LCA (e.g. mid LAD) within the previous 30 days.

          6. Known intolerance to any antiplatelet agent that would prevent a 12 month dual
             antiplatelet therapy (DAPT) duration

          7. Patients requiring additional surgery (cardiac or non-cardiac) within 3 months post
             randomization.

          8. Non-cardiac co-morbidities with a life expectancy less than 2 years.

          9. Currently participating in another trial and not yet at its primary endpoint. The
             patient is not allowed to participate in another investigational device or drug study
             for at least 12 months after enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Banning, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luca Testa, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinco San Donato</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ron van Amsterdam, PhD, DipPharMed</last_name>
    <phone>+31 (0)10 206 28 00</phone>
    <email>rvamsterdam@cardialysis.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>ITA-001</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNK-001</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IVUS</keyword>
  <keyword>PCI</keyword>
  <keyword>Left Main</keyword>
  <keyword>QCA</keyword>
  <keyword>Treatment Strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

